EUCTR2007-004465-18-SE进行中（未招募）不适用
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared With a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory Elderly Individuals Aged 70 Years and Older Who Received 1 Dose of 23vPS at Least 5 Years Before Study Enrollment
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 924 人开始时间: 2007年9月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 924
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Male or female adult 70 years of age or older at the time of enrollment.
- •[2] Documented vaccination with 1 dose of 23vPS at least 5 years before study enrollment.
- •[3] Determined by medical history, physical examination, and clinical judgment to be eligible for the study. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapya or hospitalization for worsening disease 12 weeks before receipt of the test article, are eligible.
- •[4] Able to complete an electronic diary (e-diary) and follow study procedures in the opinion of the investigator.
- •[5] Expected to be available for the duration of the trial (approximately 18 months).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[1] History of severe adverse reaction associated with a vaccine.
- •[2] Receipt of more than one 23vPS dose before study enrollment or any prior pneumococcal conjugate vaccine.
- •[3] Receipt of any vaccine within 30 days before test article administration, except influenza vaccine.
- •[4] Vaccination with a diphtheria-containing vaccine within 6 months before test article administration or anticipated receipt before study completion.
- •[5] Documented S pneumoniae infection within the past 5 years.
- •[6] Known or suspected immunodeficiency or receiving treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids, eg, for cancer, HIV or autoimmune disease. If systemic corticosteroids have been administered short term for treatment of an acute illness, subjects should be excluded from the study until corticosteroid therapy has been discontinued for at least 30 days.
- •[7] Serious chronic disorders including metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator’s opinion precludes the subject from participating in the study.
- •[8] Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care. An ambulatory subject, who is a resident of a retirement home or village, is eligible for the trial.
- •[9] Evidence of dementia or other severe cognitive impairment based on a Mini-Mental State Examination (MMSE) score of less than or equal to 21.
- •[10] Poor or missing eyesight, requiring third-party support to read.
- •[11] Receipt of any blood products, including immunoglobulin, within 6 months before test article administration or anticipated receipt before study completion.
- •[12] In the opinion of the investigator, unable to receive a vaccination in the deltoid muscle of either arm because of insufficient muscle mass or unable to grade limitation of arm movement that would interfere with the evaluation of the study objectives.
- •[13] Currently on anticoagulant therapy or a history of bleeding diathesis that would contraindicate intramuscular (IM) injection.
- •[14] Intent to receive any other investigational vaccine or agent from 1 month (30 days) before enrollment until the conclusion of the study.
- •[15] Any medical condition that would, in the opinion of the investigator, interfere with the evaluation of the study objectives.
研究者
相似试验
进行中（未招募）
不适用
Safety and immunogenicity study of a prime-boost schedule of GSK Biologicals' influenza vaccine GSK1562902A in children aged 3 to 17 years.EUCTR2011-004751-39-Outside-EU/EEAGlaxoSmithKline Biologicals520
进行中（未招募）
1 期
The effect and long-term safety of MK-0887A in children with asthmaAsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2009-010110-30-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.160
进行中（未招募）
1 期
The effect and long-term safety of MK-0887A in children with asthmaAsthmaEUCTR2009-010110-30-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.160
进行中（未招募）
1 期
The effect and long-term safety of MK-0887A in children with asthmaAsthmaEUCTR2009-010110-30-LVMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.160
进行中（未招募）
2 期
A Phase 2/3, Randomized, Active-controlled, Observer-blinded, Non-inferiority Study to Evaluate the Safety and Immunogenicity of Booster Immunization with DS-5670a/b (Bivalent: Original Strain/Omicron Strain BA.4-5) in Subjects Aged 5 to 11 Years Who Have Completed Initial Immunization with Comirnaty Intramuscular Injection (Univalent: Original Strain)JPRN-jRCT2031220665Inoguchi Akihiro210